Navigation Links
Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Date:5/18/2009

Data on frequency of resistance development and safety presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SAN DIEGO, May 18 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced new data today from multiple studies of torezolid (TR-701), a novel antibiotic that is a potent inhibitor of gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Data presented at ECCMID demonstrate that MRSA and MSSA strains exposed in vitro to torezolid developed spontaneous resistance at a 16-fold lower frequency than strains exposed to linezolid (Zyvox(R)), the only drug of the oxazolidinone class currently marketed. Poster presentations on TR-701 also highlighted data characterizing torezolid's pharmacodynamics, high intracellular concentrations and resulting bactericidal activity. Human Phase 1 clinical studies showed that oral torezolid, administered at doses from 200 to 400 mg once a day over 21 days, is safe and well tolerated, and that its oral bioavailability is not affected by the administration of food.

"These new study results presented by Trius and external investigators validate the compound's increased potency and ability to reach bacterial pathogens in high concentration inside the tissues while also supporting a favorable safety and tolerability profile," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "As a result, there is significant interest from the medical community in torezolid, a second generation oxazolidinone, especially for the treatment of infections caused by S. aureus, including MRSA."

Posters/abstracts are available on the Trius Web site at www.triusrx.com/posters.
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Atrius Health Selects rL Solutions for Improved Patient Safety and Quality of Care
2. Trius Raises $30 Million in Series B Financing
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
5. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
6. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
7. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
8. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
9. American Association for Homecare Applauds Senate Subcommittee Efforts to Prevent Waste and Fraud in Medicare; Association Presents 13-Point Legislative Plan to Stop Waste and Fraud
10. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Angeles, California (PRWEB) May 18, 2013 Online ... to be Rolex watch owners at a fraction ... collection of luxury timepieces in the world, buyers are urged ... As compared to buying a Rolex watch from a brick-and-mortar ... pre owned Rolex watches priced at unbelievable rates. Although ...
(Date:5/18/2013)... 18, 2013 MOOSGO.COM published an original art ... book features a group of artists who share their creations ... illustrations and paintings. Exclusively for iPad . , ... songs and videos that reflect the signature idiosyncrasy and passion ... the Apple iBook Store and it includes a free ...
(Date:5/18/2013)... Assisted living and retirement communities have ... comfort of their residents. Systems Technologies is well-acquainted ... effective and cost-efficient solution – VisionLink Wireless Nurse ... communications solution that helps nurses provide the highest ... privacy. , The VisionLink nurse call ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:New Art Book for iPad: Tango Art 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... (Nasdaq: RIGL ) today announced financial results for,the third ... the third quarter of 2007, Rigel reported a net loss ... loss of $11.4 million, or,$0.46 per share, in the third ... of 2007 and 2006 were 31.0 million and,25.0 million, respectively. ...
... 6 Sanofi Pasteur, the,vaccines division of sanofi-aventis ... a vaccine for the global prevention of dengue ... results are being,presented today at the American Society ... held in Philadelphia, Pennsylvania, USA. These results ...
... Ill., Nov. 5 Former Congressman,Henry J. Hyde ... nation,s top,civilian honor -- the Presidential Medal of ... "a better country" because of Mr. Hyde,s 32 ... ceremony live from Marianjoy Rehabilitation,Hospital where he is ...
... patients and patient advocates, DETROIT, Nov. 5 ... the United States. More than 60 percent of,lung cancer ... About,70 percent of patients are diagnosed at a late ... years., The Barbara Ann Karmanos Cancer Institute and ...
... ,07 Gold Award winner, Opus(TM) Overbed Table notches second ... major industry ... Steelcase, a healthcare,environments company, today announced that it has earned ... in Dallas,for its Opus(TM) Overbed Table. (Photo: http://www.newscom.com/cgi-bin/prnh/20071105/AQM210 ...
... Toxocara infection in young children and ... 20 raises public health concerns, BEL AIR, Md., Nov. ... with Toxocara, or internal roundworms, contracted,from dogs and cats. That,s ... Prevention (CDC) study announced today at the American,Society of Tropical ...
Cached Medicine News:Health News:Rigel Announces Third Quarter 2007 Financial Results 2Health News:Rigel Announces Third Quarter 2007 Financial Results 3Health News:Rigel Announces Third Quarter 2007 Financial Results 4Health News:Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine 2Health News:Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine 3Health News:Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine 4Health News:Former Congressman Hyde Awarded Presidential Medal of Freedom While Receiving Medical Rehabilitation at Marianjoy 2Health News:BREATHE Lung Cancer Conference, Nov. 30, Attracts World Renowned Physicians and Speakers 2Health News:BREATHE Lung Cancer Conference, Nov. 30, Attracts World Renowned Physicians and Speakers 3Health News:Nurture by Steelcase Wins Nightingale Award for Opus(TM) Overbed Table 2Health News:CDC Reports Prevalence of Worms Transmitted by Dogs and Cats to Humans is Higher Than Previously Understood 2Health News:CDC Reports Prevalence of Worms Transmitted by Dogs and Cats to Humans is Higher Than Previously Understood 3
(Date:5/17/2013)...  Atossa Genetics, Inc. (NASDAQ: ATOS ), The ... , Chief Financial Officer & General Counsel, will present ... May 30, 2013, in New York City ... Company,s presentation is scheduled to begin at 3:30 p.m. EDT ... the webcast, go to www.atossagenetics.com . For ...
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
(Date:5/16/2013)... CHICAGO, Ill. and MECHELEN, Belgium ... (Euronext: GLPG) and AbbVie (NYSE: ABBV ) ... collaboration to include Crohn,s disease.  Galapagos will fund and ... is designed to facilitate rapid progression into Phase 3.  ... 2015, AbbVie will pay Galapagos $50 million.  The terms ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... Extensive Report of Bile Acid Aberration in Type 2 Diabetes Patients ... ... June 9 /PRNewswire-FirstCall/,-- KineMed, Inc., and Daiichi Sankyo, Inc., announced that ... with type 2,diabetes which may suggest a newly identified underlying disorder., ...
... investigational regimen resulted in 82 percent overall survival and 78 ... ... conducted in this ... patient population, LUGANO, Switzerland, June 9 In an oral,presentation today at ...
Cached Medicine Technology:New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 2New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 3New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 4New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 5New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 6New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 7Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 2Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 3Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 4
... single use, disposable device that is specifically ... after the needle is in place. ,It ... from accidental movement by contact, during patient ... patient confidence in your staff and your ...
... for high volume laboratories, the AU2700 automates ... time. This high-speed analyzer delivers true random ... test results per hour (up to 2133 ... tests on-board. Consolidate with Olympus 122 test ...
... The EPO ELISA is intended for the ... This assay is intended for in vitro diagnostic ... anemias and polycythemias. With the advent of the ... to increase red blood cell mass, an erythropoietin ...
... innovative PoleStar N20, exclusively distributed by ... MRI. Combining intra-operative imaging with ... system, PoleStar N20 is one of ... today. , , Exceptional image quality ...
Medicine Products: